Diabetes PubMed

The current review of the published literature supports that insulin lispro is a safe alternative to human insulin with similar perinatal outcomes and potentially improved glycemic control in the management of diabetes in pregnancy.

Our findings suggest that lispro is likely to improve quality-adjusted life expectancy (QALE), reduce frequency of diabetes-related complications and lifetime medical costs compared with regular human insulin (RHI).

In this elderly subgroup post-hoc analysis, LM25 (lispro 25%/insulin lispro protamine suspension 75%) demonstrated a lower endpoint HbA(1c) and a higher % of patients reaching HbA(1c) target of < 7.0%, but with more weight gain and higher rates of hypoglycaemia compared to glargine.